Gilead Sciences completes acquisition of CV Therapeutics

On April 17, 2009, CV Therapeutics merged with a wholly-owned subsidiary of Gilead. As a result of the merger, each outstanding share of CV Therapeutics not owned by Gilead, its subsidiaries or CV Therapeutics has been automatically converted into the right to receive $20 in cash, without interest, subject to appraisal rights.

CV Therapeutics stockholders who did not tender their shares will receive a notice of merger and a letter of transmittal that will instruct them as to how to receive the merger consideration. The merger follows a cash tender offer for all outstanding shares of CV Therapeutics common stock at $20 per share, which was completed on April 14, 2009.